Adamis Pharmaceuticals Begins Prostate Cancer Trial
Published: Aug 30, 2011
SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (OTCBB: ADMP) announced today that it enrolled the first patient in its Phase 1/2a clinical prostate study. Adamis’ drug, APC-100, will be used to treat men with castrate-resistant prostate cancer (CRPR). Each patient will be assessed for toxicity, biochemical (Prostate Specific Antigen), radiographic and clinical responses. The study began at the University of Wisconsin Carbone Cancer Center and will be extended to Wayne State University Karmanos Cancer Institute. Both of these institutions are currently named within “The Prostate Cancer Clinical Trials Consortium.” This Clinical Trials Consortium or Prostate Cancer Centers of Excellence is made up of a 13 member clinical trial research group. They capitalize on their scientific expertise and unique institutional resources in order to rapidly bring new discoveries to prostate cancer patients.